Company Overview and News
2018-09-07 reuters - 1
Sept 7 (Reuters) - Canada’s main stock index fell on Friday after domestic data showed a surprise decline in jobs in August and as trade and tariff worries continued to weigh.
EGHSF SWIR CVE ACB ESL APH ACBFF CVE TCLAF SW TCLCF APHQF
2018-08-03 seekingalpha - 2
Good afternoon. My name is Susan, and I will be your conference operator today. At this time, I’d like to welcome everyone to the Sierra Wireless, Second Quarter Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks there will be a question-and-answer session. [Operator Instructions] Thank you.
SWIR FDC SW NMRX ALTR
Sierra Wireless (SWIR - Free Report) just came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.30 per share a year ago. These figures are adjusted for non-recurring items.
SWIR SHAK SW
2018-07-24 investorplace - 4
Just for the record, “trillion” means twelve zeroes … with a number in front of all of them. In this case, experts are putting a “1” in front of those twelve zeroes to describe how big the market for Internet of Things stocks should be by 2025.
IBM MRVL GE GEC CY SW NVDA SWIR BABA T HON STM GNE QCOM
2018-07-20 zacks - 3
Skyworks Solutions Inc. (SWKS - Free Report) reported third-quarter fiscal 2018 non-GAAP earnings of $1.64 per share, which beat the Zacks Consensus Estimate as well as management guidance by a nickel. The figure improved 4.5% from the year-ago quarter. Revenues of $894.3 million were down 0.7% year over year, primarily due to weakness in mobile business and loss of ZTE revenues (which usually contributes $25-$30 million per quarter).
SWIR SWKS QRVO KDP SW GM QCOM
2018-07-20 seekingalpha - 1
Good afternoon, and welcome to Skyworks Solutions' Third Quarter Fiscal Year 2018 Earnings Call. This call is being recorded. At this time, I will turn the call over to Mitch Haws, Vice President of Investor Relations for Skyworks. Mr. Haws please go ahead.
CHLKF SW 0941 SWIR SWKS 0762 CHL CHUFF MS CHU
Good day, ladies and gentlemen, and welcome to the First Quarter 2019 TESSCO Technologies Incorporated Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we'll conduct a question-and-answer session, and instructions will be given at that time. [Operator Instructions] As a reminder, this conference call is being recorded.
SWIR SW TESS
Sierra Wireless, Inc. (SWIR - Free Report) recently unveiled the new AirLink MG90 high-performance LTE-Advanced Pro multi-network vehicle router, designed specifically to provide secure and constant connectivity for mission critical applications. This is the first device to be deemed FirstNet Ready. Understanding FirstNet To better understand the motive behind Sierra’s newly-launched router, let us first talk about what FirstNet is.
SWIR MSI CMTL SW PII
Our connection to the internet took on a new and more involved form when much of the connectivity moved from the PC to the smartphone. This ushered in a whole host of applications that changed the way we live.
SWIR SWKS TXN ARW SW NYTAB MCHP INTC
2018-06-22 seekingalpha - 1
Disclaimer: This material is furnished by Lerna Capital LLC or affiliates (collectively “Lerna”). This material is for information purposes only and is not an offer or a solicitation to subscribe for or purchase the securities mentioned. This material is not intended to provide a sufficient basis on which to make an investment decision. All market and commercial data in this thesis are not warranted as to completeness or accuracy.
SWIR INSG SW MIFI
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TSX:SW / Sierra Wireless on message board site Silicon Investor.